WEKO3
アイテム
{"_buckets": {"deposit": "06033790-f321-4275-a1df-4d4965bc49b3"}, "_deposit": {"created_by": 2, "id": "3727", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "3727"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00003727", "sets": ["30"]}, "author_link": ["15172", "15168", "15174", "15167", "15175", "15178", "15180", "15169", "15170", "15166", "15173", "15179", "15177", "15176", "15171"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2016-07-29", "bibliographicIssueDateType": "Issued"}, "bibliographicPageStart": "82", "bibliographicVolumeNumber": "16", "bibliographic_titles": [{"bibliographic_title": "BMC Gastroenterology"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Background: There are few reports of the efficacy of adalimumab (ADA) for clinical remission and preventing postoperative recurrence in Crohn\u0027s disease (CD) in Asian real practice settings. We conducted a Japanese multicenter retrospective observational study. Methods: We evaluated patients with CD who were treated with ADA at 11 medical institutions in Japan to\ninvestigate the clinical efficacy of remission up to 52 weeks and the associated factors to achieve remission with a CD Activity Index (CDAI) \u003c 150. The effects of preventing postoperative recurrence were also evaluated. Results: In 62 patients, the remission rates were 33.9, 74.2, 75.8, 77.4, and 66.1 % at 0, 4, 12, 26, and 52 weeks,\nrespectively. Although 10 patients discontinued treatment due to primary nonresponse, secondary nonresponse, or adverse events, the ongoing treatment rate at 52 weeks was 83.9 %. Comparison of remission and non-remission on univariate analysis identified colonic type and baseline CDAI value as significant associated factors (P \u003c 0.05). In 16\npatients who received ADA to prevent postoperative recurrence, the clinical remission maintenance rate was 93.8 %\nand the mucosal healing rate was 64.3 % during a mean postoperative follow-up period of 32.3 months. Conclusions: ADA effectively induced remission and prevented postoperative recurrence in patients with CD in a real practice setting.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "BMC Gastroenterology, 16, 82; 2016", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "BioMed Central"}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isIdenticalTo", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1186/s12876-016-0501-9", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "c 2016 The Author(s)."}, {"subitem_rights": "This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated."}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1471230X", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_970fb48d4fbd8a85", "subitem_version_type": "VoR"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Takeshima, Fuminao"}], "nameIdentifiers": [{"nameIdentifier": "15166", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yoshikawa, Daisuke"}], "nameIdentifiers": [{"nameIdentifier": "15167", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Higashi, Syuntaro"}], "nameIdentifiers": [{"nameIdentifier": "15168", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Morisaki, Tomohito"}], "nameIdentifiers": [{"nameIdentifier": "15169", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Oda, Hidetoshi"}], "nameIdentifiers": [{"nameIdentifier": "15170", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ikeda, Maho"}], "nameIdentifiers": [{"nameIdentifier": "15171", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Machida, Haruhisa"}], "nameIdentifiers": [{"nameIdentifier": "15172", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Matsushima, Kayoko"}], "nameIdentifiers": [{"nameIdentifier": "15173", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Minami, Hitomi"}], "nameIdentifiers": [{"nameIdentifier": "15174", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Akazawa, Yuko"}], "nameIdentifiers": [{"nameIdentifier": "15175", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamaguchi, Naoyuki"}], "nameIdentifiers": [{"nameIdentifier": "15176", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ohnita, Ken"}], "nameIdentifiers": [{"nameIdentifier": "15177", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Isomoto, Hajime"}], "nameIdentifiers": [{"nameIdentifier": "15178", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ueno, Masato"}], "nameIdentifiers": [{"nameIdentifier": "15179", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakao, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "15180", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-21"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "BMCGas16_82.pdf", "filesize": [{"value": "604.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 604900.0, "url": {"label": "BMCGas16_82.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/3727/files/BMCGas16_82.pdf"}, "version_id": "403fdf33-d26e-4483-954a-fbeaf63909bd"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "Adalimumab", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Crohn’s disease", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Preventing postoperative recurrence", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Japanese patients", "subitem_subject_scheme": "Other"}, {"subitem_subject": "Real practice", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan"}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/36911", "pubdate": {"attribute_name": "公開日", "attribute_value": "2016-10-27"}, "publish_date": "2016-10-27", "publish_status": "0", "recid": "3727", "relation": {}, "relation_version_is_last": true, "title": ["Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan"], "weko_shared_id": -1}
Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan
http://hdl.handle.net/10069/36911
http://hdl.handle.net/10069/369113441d05d-e60c-4e5c-80cf-90c9750b9c57
名前 / ファイル | ライセンス | アクション |
---|---|---|
BMCGas16_82.pdf (604.9 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2016-10-27 | |||||
タイトル | ||||||
タイトル | Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan | |||||
言語 | ||||||
言語 | eng | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Adalimumab | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Crohn’s disease | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Preventing postoperative recurrence | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Japanese patients | |||||
キーワード | ||||||
主題Scheme | Other | |||||
主題 | Real practice | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Takeshima, Fuminao
× Takeshima, Fuminao× Yoshikawa, Daisuke× Higashi, Syuntaro× Morisaki, Tomohito× Oda, Hidetoshi× Ikeda, Maho× Machida, Haruhisa× Matsushima, Kayoko× Minami, Hitomi× Akazawa, Yuko× Yamaguchi, Naoyuki× Ohnita, Ken× Isomoto, Hajime× Ueno, Masato× Nakao, Kazuhiko |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Background: There are few reports of the efficacy of adalimumab (ADA) for clinical remission and preventing postoperative recurrence in Crohn's disease (CD) in Asian real practice settings. We conducted a Japanese multicenter retrospective observational study. Methods: We evaluated patients with CD who were treated with ADA at 11 medical institutions in Japan to investigate the clinical efficacy of remission up to 52 weeks and the associated factors to achieve remission with a CD Activity Index (CDAI) < 150. The effects of preventing postoperative recurrence were also evaluated. Results: In 62 patients, the remission rates were 33.9, 74.2, 75.8, 77.4, and 66.1 % at 0, 4, 12, 26, and 52 weeks, respectively. Although 10 patients discontinued treatment due to primary nonresponse, secondary nonresponse, or adverse events, the ongoing treatment rate at 52 weeks was 83.9 %. Comparison of remission and non-remission on univariate analysis identified colonic type and baseline CDAI value as significant associated factors (P < 0.05). In 16 patients who received ADA to prevent postoperative recurrence, the clinical remission maintenance rate was 93.8 % and the mucosal healing rate was 64.3 % during a mean postoperative follow-up period of 32.3 months. Conclusions: ADA effectively induced remission and prevented postoperative recurrence in patients with CD in a real practice setting. |
|||||
書誌情報 |
BMC Gastroenterology 巻 16, p. 82, 発行日 2016-07-29 |
|||||
出版者 | ||||||
出版者 | BioMed Central | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1471230X | |||||
DOI | ||||||
関連タイプ | isIdenticalTo | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1186/s12876-016-0501-9 | |||||
権利 | ||||||
権利情報 | c 2016 The Author(s). | |||||
権利 | ||||||
権利情報 | This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. | |||||
著者版フラグ | ||||||
出版タイプ | VoR | |||||
出版タイプResource | http://purl.org/coar/version/c_970fb48d4fbd8a85 | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | BMC Gastroenterology, 16, 82; 2016 |